RU2020126774A - Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения - Google Patents
Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения Download PDFInfo
- Publication number
- RU2020126774A RU2020126774A RU2020126774A RU2020126774A RU2020126774A RU 2020126774 A RU2020126774 A RU 2020126774A RU 2020126774 A RU2020126774 A RU 2020126774A RU 2020126774 A RU2020126774 A RU 2020126774A RU 2020126774 A RU2020126774 A RU 2020126774A
- Authority
- RU
- Russia
- Prior art keywords
- agent
- conjugate
- subject
- carrier
- tumor
- Prior art date
Links
- 239000012216 imaging agent Substances 0.000 title claims 11
- 231100000331 toxic Toxicity 0.000 title claims 3
- 230000002588 toxic effect Effects 0.000 title claims 3
- 238000012790 confirmation Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 33
- 238000000034 method Methods 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 229920001223 polyethylene glycol Polymers 0.000 claims 14
- 239000002738 chelating agent Substances 0.000 claims 9
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000012544 monitoring process Methods 0.000 claims 6
- 238000002600 positron emission tomography Methods 0.000 claims 6
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical group CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 4
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229920002521 macromolecule Polymers 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 4
- 230000014759 maintenance of location Effects 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 102000004459 Nitroreductase Human genes 0.000 claims 2
- 239000012661 PARP inhibitor Substances 0.000 claims 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 238000007068 beta-elimination reaction Methods 0.000 claims 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960000958 deferoxamine Drugs 0.000 claims 2
- 229930013356 epothilone Natural products 0.000 claims 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 108020001162 nitroreductase Proteins 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000017854 proteolysis Effects 0.000 claims 2
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical class OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 230000009919 sequestration Effects 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 230000001839 systemic circulation Effects 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims 2
- 229960000977 trabectedin Drugs 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- JZCWLJDSIRUGIN-UHFFFAOYSA-N 3-[3-[4-(methylaminomethyl)phenyl]-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine Chemical compound C1=CC(CNC)=CC=C1C1=NOC(C=2C(=NC=C(N=2)C=2C=CC(=CC=2)S(=O)(=O)C(C)C)N)=C1 JZCWLJDSIRUGIN-UHFFFAOYSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- 102000000872 ATM Human genes 0.000 claims 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims 1
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims 1
- 229950004707 rucaparib Drugs 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyethers (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617095P | 2018-01-12 | 2018-01-12 | |
| US62/617,095 | 2018-01-12 | ||
| US201862674483P | 2018-05-21 | 2018-05-21 | |
| US62/674,483 | 2018-05-21 | ||
| US201862700147P | 2018-07-18 | 2018-07-18 | |
| US62/700,147 | 2018-07-18 | ||
| US201862711423P | 2018-07-27 | 2018-07-27 | |
| US201862711421P | 2018-07-27 | 2018-07-27 | |
| US62/711,423 | 2018-07-27 | ||
| US62/711,421 | 2018-07-27 | ||
| US201862716788P | 2018-08-09 | 2018-08-09 | |
| US201862716796P | 2018-08-09 | 2018-08-09 | |
| US62/716,796 | 2018-08-09 | ||
| US62/716,788 | 2018-08-09 | ||
| PCT/US2019/013306 WO2019140266A1 (en) | 2018-01-12 | 2019-01-11 | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020126774A true RU2020126774A (ru) | 2022-02-14 |
Family
ID=67218383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020126774A RU2020126774A (ru) | 2018-01-12 | 2019-01-11 | Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20200360545A1 (https=) |
| EP (2) | EP3737383A4 (https=) |
| JP (3) | JP2021510701A (https=) |
| KR (2) | KR20200109345A (https=) |
| CN (2) | CN111587126A (https=) |
| AU (2) | AU2019208024A1 (https=) |
| CA (2) | CA3087628A1 (https=) |
| MX (3) | MX2020007306A (https=) |
| RU (1) | RU2020126774A (https=) |
| WO (2) | WO2019140266A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| CN114615978A (zh) * | 2019-08-28 | 2022-06-10 | 普罗林科斯有限责任公司 | Dna损伤响应的偶联抑制剂 |
| CN119213060A (zh) * | 2022-04-14 | 2024-12-27 | 国立研究开发法人量子科学技术研究开发机构 | 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒 |
| WO2024030998A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Methods of treating cancer with long-acting topoisomerase i inhibitor |
| WO2024031005A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Treating cancer with long-acting topoisomerase i inhibitor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998030575A1 (en) | 1997-01-08 | 1998-07-16 | Proligo Llc | Bioconjugation of macromolecules |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20040176270A1 (en) | 2002-07-12 | 2004-09-09 | Biomarin Pharmaceutical Inc. | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| EP1580216B1 (en) | 2002-10-31 | 2014-05-14 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| ES2629696T3 (es) | 2003-09-17 | 2017-08-14 | Nektar Therapeutics | Profármacos poliméricos multibrazo |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| MX2009002855A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales. |
| WO2009141826A2 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| CA2738807A1 (en) | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| JP2012509469A (ja) | 2008-11-18 | 2012-04-19 | バクスター・インターナショナル・インコーポレイテッド | ポリエチレングリコールサンプルの多分散度および／または分子量分布を決定する方法 |
| WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| ME03396B (me) | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| US8703907B2 (en) | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| TW201215412A (en) | 2010-08-30 | 2012-04-16 | Sun Pharma Advanced Res Co Ltd | Stable pharmaceutical composition |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| IN2014MN01819A (https=) * | 2012-03-05 | 2015-07-03 | Univ Ramot | |
| TWI486341B (zh) * | 2012-05-18 | 2015-06-01 | 高雄醫學大學 | 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法 |
| US9863949B2 (en) * | 2013-05-31 | 2018-01-09 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents |
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015118338A1 (en) * | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| WO2015183876A1 (en) * | 2014-05-28 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Bimodal fluorophore-labeled liposomes and associated methods and systems |
| CA2957721C (en) * | 2014-08-13 | 2021-04-13 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| WO2016028636A1 (en) | 2014-08-16 | 2016-02-25 | Memorial Sloan Kettering Cancer Center | Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods |
| JP6378584B2 (ja) | 2014-08-29 | 2018-08-22 | キヤノン株式会社 | 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム |
| US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
| PL3560924T3 (pl) | 2015-04-02 | 2021-10-11 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| CA2980462C (en) * | 2015-04-07 | 2023-08-01 | The Curators Of The University Of Missouri | Nanoparticle immunoconjugates |
| WO2016176462A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| EP3337467B1 (en) * | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US10821195B2 (en) | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| US11154538B2 (en) | 2016-02-29 | 2021-10-26 | Synta Pharmaceuticals Corporation | Combination therapy for treatment of ovarian cancer |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| JP7379795B2 (ja) | 2016-04-27 | 2023-11-15 | イミューノメディクス、インコーポレイテッド | チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果 |
| CN109069666B (zh) | 2016-04-29 | 2023-04-04 | 纪念斯隆凯特琳癌症中心 | 使靶向颗粒穿透、分布和响应于恶性脑肿瘤中的组合物和方法 |
| CN106084005B (zh) * | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| CN107050471A (zh) | 2016-12-27 | 2017-08-18 | 中国药科大学 | 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用 |
-
2019
- 2019-01-11 MX MX2020007306A patent/MX2020007306A/es unknown
- 2019-01-11 CA CA3087628A patent/CA3087628A1/en active Pending
- 2019-01-11 WO PCT/US2019/013306 patent/WO2019140266A1/en not_active Ceased
- 2019-01-11 JP JP2020538819A patent/JP2021510701A/ja active Pending
- 2019-01-11 AU AU2019208024A patent/AU2019208024A1/en not_active Abandoned
- 2019-01-11 RU RU2020126774A patent/RU2020126774A/ru unknown
- 2019-01-11 EP EP19738883.8A patent/EP3737383A4/en not_active Withdrawn
- 2019-01-11 JP JP2020538844A patent/JP2021510702A/ja active Pending
- 2019-01-11 US US16/961,633 patent/US20200360545A1/en not_active Abandoned
- 2019-01-11 EP EP19738881.2A patent/EP3737416A4/en not_active Withdrawn
- 2019-01-11 CA CA3087967A patent/CA3087967A1/en active Pending
- 2019-01-11 WO PCT/US2019/013314 patent/WO2019140271A2/en not_active Ceased
- 2019-01-11 MX MX2020007442A patent/MX2020007442A/es unknown
- 2019-01-11 KR KR1020207023338A patent/KR20200109345A/ko not_active Ceased
- 2019-01-11 CN CN201980008252.XA patent/CN111587126A/zh active Pending
- 2019-01-11 AU AU2019206623A patent/AU2019206623A1/en not_active Abandoned
- 2019-01-11 US US16/961,640 patent/US11730836B2/en active Active
- 2019-01-11 KR KR1020207023337A patent/KR20200110377A/ko not_active Ceased
- 2019-01-11 CN CN201980008227.1A patent/CN111587115A/zh active Pending
-
2020
- 2020-07-13 MX MX2023005786A patent/MX2023005786A/es unknown
-
2023
- 2023-03-07 US US18/118,650 patent/US20230321286A1/en not_active Abandoned
- 2023-07-11 US US18/220,742 patent/US20240082436A1/en not_active Abandoned
- 2023-10-31 JP JP2023186470A patent/JP7703001B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020007306A (es) | 2020-09-25 |
| KR20200109345A (ko) | 2020-09-22 |
| CN111587126A (zh) | 2020-08-25 |
| MX2023005786A (es) | 2023-05-29 |
| US20230321286A1 (en) | 2023-10-12 |
| JP2024012442A (ja) | 2024-01-30 |
| US20200397778A1 (en) | 2020-12-24 |
| EP3737416A1 (en) | 2020-11-18 |
| JP2021510702A (ja) | 2021-04-30 |
| RU2020126853A3 (https=) | 2022-02-14 |
| CA3087967A1 (en) | 2019-07-18 |
| EP3737383A4 (en) | 2021-12-15 |
| RU2020126853A (ru) | 2022-02-14 |
| CN111587115A (zh) | 2020-08-25 |
| AU2019206623A1 (en) | 2020-07-16 |
| AU2019208024A1 (en) | 2020-08-13 |
| US11730836B2 (en) | 2023-08-22 |
| US20200360545A1 (en) | 2020-11-19 |
| WO2019140271A2 (en) | 2019-07-18 |
| WO2019140271A3 (en) | 2019-08-22 |
| JP2021510701A (ja) | 2021-04-30 |
| EP3737416A4 (en) | 2022-03-30 |
| EP3737383A2 (en) | 2020-11-18 |
| KR20200110377A (ko) | 2020-09-23 |
| MX2020007442A (es) | 2020-09-14 |
| CA3087628A1 (en) | 2019-07-18 |
| US20240082436A1 (en) | 2024-03-14 |
| WO2019140266A1 (en) | 2019-07-18 |
| JP7703001B2 (ja) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020126774A (ru) | Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения | |
| AU2010200056B2 (en) | Dendrimer based compositions and methods of using the same | |
| US20150265731A1 (en) | Method to improve the tumor diagnostic efficiency of multivalent ligands by regulating the stoichiometric ratio between inner surface functionalities and ligand moieties for tumor targeting | |
| JP2021510701A5 (https=) | ||
| Goos et al. | Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue | |
| ES2745745T3 (es) | Polipéptidos entrecruzados autoensamblados en forma de estrella y su uso como transportadores en aplicaciones biomédicas | |
| Zhao et al. | Polyethylenimine-based theranostic nanoplatform for glioma-targeting single-photon emission computed tomography imaging and anticancer drug delivery | |
| KR102780263B1 (ko) | p-보로노페닐알라닌 유도체 및 그것을 포함하는 조성물, 그리고 그들을 제조하기 위한 키트 | |
| US20190022259A1 (en) | Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions | |
| Fan et al. | Cathepsin S-cleavable, multi-block HPMA copolymers for improved SPECT/CT imaging of pancreatic cancer | |
| Liu et al. | Synthesis, biodistribution, and imaging of PEGylated-acetylated polyamidoamine dendrimers | |
| Kostka et al. | Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models | |
| Lee et al. | Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: Importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug | |
| Huang et al. | Liver‐targeting doxorubicin‐conjugated polymeric prodrug with pH‐triggered drug release profile | |
| US20150031988A1 (en) | Nano-particles for internal radiation therapy of involved area, and therapy system | |
| CA3095137A1 (en) | Pharmaceutical compositions containing polyrotaxanes | |
| WO2025059124A1 (en) | N-oxide based zwitterionic near infrared fluorophore imaging agents and methods of use therefor | |
| JPWO2019140266A5 (https=) | ||
| Vats et al. | Assessment of 177Lu‐labeled carboxyl‐terminated polyamidoamine (PAMAM) dendrimer‐RGD peptide conjugate | |
| JP2019085438A (ja) | 温度応答性ポリマー及びそれを含む組成物 | |
| WO2025240771A1 (en) | Small zwitterionic multimeric targeted drugs and methods of use and manufacture thereof | |
| Yuan et al. | Synthesis and characterization of poly (HPMA)‐APMA‐DTPA‐99mTc for imaging‐guided drug delivery in hepatocellular carcinoma | |
| KR101725281B1 (ko) | 고분자 복합체 및 광역학적 화학요법 치료제 | |
| US20250082795A1 (en) | Combinations of imaging agent conjugates and application thereof | |
| US20250360157A1 (en) | Cytotoxic fluoropyrimidine polymers and methods of use thereof |